DNA Vaccines Market

The Dna Vaccines Market is valued at USD 576.1 Mn in 2026 and is projected to reach USD 915.8 Mn, growing at a CAGR of 7% by 2033

Growing Prevalence of Cancer and Infectious Diseases will Drive DNA Vaccines Market Ahead

DNA vaccines offer a novel method of immunising people against not only viral and bacterial diseases, but a host of parasitic and fungal infections as well. The vaccines use engineered DNA to induce an immunologic response in the host against bacteria, parasites, viruses, and potentially cancer. While still in development, this vaccination technology offers some distinct advantages that would make it an invaluable asset in vaccination, and immunisation programmes. This is expected to work on favour of global DNA vaccines market. The third-generation vaccine technology is rapidly improving. Researchers are studying DNA vaccines to fight HIV and certain cancers. One of the biggest challenges associated with DNA vaccines is their low immunogenicity in larger animals, and humans. Higher amounts of DNA within the range of 5 to 20 mg would need to be injected into an average-sized human to increase the immunogenicity of DNA-based vaccines. Another challenge of DNA-based vaccines involves the optimisation of transfection.

The rise in rapid development in immunology and molecular biology is a vital factor in escalating market growth, rise in cases of HIV, hepatitis, and others, increase in government investment in DNA vaccines, and rise in the number of antibiotics resistant pathogens have created the need for effective and low-cost vaccination, which acts as one of the major factors driving the expansion of DNA vaccines market. The rising technological developments and modernisation in healthcare equipment, rising R&D efforts in the healthcare sector, and rising emerging markets will generate new chances for DNA vaccines market during the anticipated period.

Increased instances of cancers, and infectious diseases in humans and animals, as well as increased demand for DNA vaccines due to benefits such as the reduced risk of infection, accessible transportation, and room temperature stability, are some of the factors driving the DNA vaccine market. An aging population and increased established cancer risk factors may contribute to cancer rates. Therapeutic DNA cancer vaccines are now seen as an up-and-coming technique for stimulating the immune system's response to cancer. In 2020, there will be an estimated 18.1 million cancer cases worldwide. Men made up 9.3 million cases, while women made up 8.8 million. The continual increase in the number of cancer cases will propel the use of DNA vaccines in the coming years, thereby fuelling the growth of DNA vaccines market.

The continual climate change, rising urbanisation, and shifting land-use patterns will all raise the likelihood of infectious diseases like tuberculosis, Covid-19, Swine Flu, and other outbreaks in the future. Climate change, in particular, may modify the global pathogen spectrum, allowing illnesses, particularly vector-borne infections, to spread to new areas.  DNA vaccines encode the antigens, which primarily evoke a humoral immune response comparable to a normal condition. In 2020, an estimated 10 million individuals had tuberculosis (TB). 5.6 million males, 3.3 million women, and 1.1 million children make up the population. The use of DNA vaccines will thus increase with the growing number of infectious diseases, in turn accelerating the expansion of DNA vaccines market.

Veterinary Hospitals Dominate in Line with Increasing in Pet and Poultry Population

Veterinary hospitals will hold the largest market share in the forecast period and are expected to maintain their dominance throughout the forecast period due to an increase in animal disease incidences, an increase in animal hospital admissions for vaccine doses, and the availability of trained veterinarians in hospitals. The increase in pet population is driving the industry, not only in the short term when pets need immunizations, initial inspections, or neutering, but also considerably in the long term as they age and require more veterinary intervention. Along with the pet population, the global cattle population has grown significantly during the last decade. The growing demand for animal products has sparked animal production worldwide. Population expansion, lifestyle and nutritional changes, and increased demand for veterinary services have contributed to segment growth.

North America will Acquire the Largest Market Share due to the Increased Prevalence of Diseases.

North America is expected to hold a considerable position in the global market based on revenue share and growth potential. This dominance in the region is due to the approval of specific treatments only in the regional market. The increased spending on animal healthcare increased purchasing power, and several significant market competitors in the region are contributing to market growth. Well-established veterinary organisational structures have also been essential in driving expansion avenues in the regional industry. North America dominates the market for deoxyribonucleic acid (DNA) vaccines due to rapid development in immunology and molecular biology, an increase in the cases of HIV, cancer, hepatitis, and other diseases, an increase in government investment in DNA vaccines, and an increase in the number of antibiotic-resistant pathogens. According to the CDC, approximately 2.8 million antibiotic-resistant infections occur in the US, and about 35,000 patients die from antibiotic-resistant diseases. The country's growing number of such conditions will propel regional market growth.

The Asia Pacific DNA vaccines market is primarily driven by several key drivers, including increasing investments in DNA vaccine R&D, particularly in third-generation vaccination technology, improving clinical trials, extensive government support, and well-established healthcare facilities and infrastructure. The expanding target population base with significant unmet clinical needs, rising disposable money, and rising knowledge of the benefits of immunisation in underdeveloped nations. The Japanese government's assistance in performing clinical studies for the development of DNA vaccines is primarily driving the country's DNA vaccine market expansion. In December 2020, AnGes, a Japanese biopharmaceutical company, announced that it had begun phase 2 clinical trials of its DNA vaccine against coronavirus. This is likely to propel the growth of DNA vaccines market in the region.

 

• BOEHRINGER INGELHEIM GmbH (MERIAL)
• VIATRIS INC. (ROTTAPHARM BIOTECH)
• GENEONE LIFE SCIENCE
• TAKARA HOLDINGS (TAKARA BIO)
• ZYDUS CADILA
• INOVIO PHARMACEUTICALS (VGX ANIMAL HEALTH)
• GENEXINE, INC
• ZOETIS INC. (FORT DODGE ANIMAL HEALTH)
• ELI-LILLY (NOVARTIS ANIMAL HEALTH)
• GEOVAX LABS, INC.

Global DNA Vaccines Market is Segmented as Below:

By Product Type

• Oncept
• West Nile-Innovator
• Apex-IHN

By Type

• Therapeutic Vaccines
• Prophylactic Vaccines

By End User

• Veterinary Clinics
• Veterinary Hospitals

By Region

• North America